TENNESSEE MEDICAID LOSEC COVERAGE RECOMMENDED
TENNESSEE MEDICAID LOSEC COVERAGE RECOMMENDED by the state's formulary advisory committee May 30. The committee urged that Merck's Losec (omeprazole) be added to the Medicaid formulary for its current indications, gastroesophageal reflux disease and Zollinger-Ellison syndrome. FDA's Gastrointestinal Drugs Advisory Committee recently advised that the drug also should be approved for the treatment of acute and refractory duodenal ulcers ("The Pink Sheet" May 28, p. 3), but the Medicaid program is unlikely to consider adding these indications to the formulary until FDA approval is given. Adding Losec to Tennessee's formulary is complicated by the state's decision in October to remove Glaxo's Zantac from the formulary due primarily to expense. With the anticipation that Losec will be more costly, officials said they are trying to come up with a policy that is fair to both products. The recommendation in favor of Losec may be good news for Zantac (ranitidine), in that the state agency's formulary decision is likely to apply to both products: if the state adds Losec to the formulary, it may also consider bringing back Zantac. The formulary committee's recommendations are advisory, although the state adopts most of them. Tennessee Medicaid already has approved the panel's recommendations to list Pfizer's oral antifungal Diflucan, Ciba-Geigy's Anafranil for obsessive-compulsive disorders, Searle's beta-blocker Kerlone, and Syntex' Synarel nasally delivered endometriosis treatment. The state already is reimbursing Lilly's Prozac for both depression and obsessive-compulsive disorders. Based on product costs and dosages being used, the state estimates that Anafranil could cost the state as little as one-fifth as much as Prozac for this indication, an official said. Tennessee also has been looking at Sandoz' anti-schizophrenia drug Clozaril but plans to hold off on coverage until it gets a breakdown of drug costs compared to patient monitoring costs under Sandoz' special distribution system (see related item, T&G-10).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth